Breaking News

U.S. Said to Limit Visitors From Ebola Nations to Five Airports
Tweet TWEET

Data Presentations, FDA Approvals, Board Appointments, Updated Clinical Results and New Contracts - Research Report on Vertex,

   Data Presentations, FDA Approvals, Board Appointments, Updated Clinical
     Results and New Contracts - Research Report on Vertex, Celgene, NPS
                    Pharmaceuticals, Cyclacel and BioCryst

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 25, 2013

NEW YORK, September 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), Celgene Corporation (NASDAQ:
CELG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Cyclacel Pharmaceuticals,
Inc. (NASDAQ: CYCC), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report

On September 3, 2013, Vertex Pharmaceutical Inc. (Vertex) announced that five
abstracts from its Cystic Fibrosis (CF) research and development program will
be presented at the 27th Annual North American Cystic Fibrosis Conference
(NACFC) in Salt Lake City, Utah between October 17 and October 19, 2013.
Vertex informed that data from a Phase 3 study of ivacaftor in non-G551D
gating mutations will be presented as well as long-term safety and efficacy
data for KALYDECO™ (ivacaftor) from the PERSIST open-label rollover study.
Fred Van Goor, Ph.D., Head of Biology for Vertex's CF program, and David
Rodman, M.D., Vice President of Clinical Development for Vertex's CF program,
will participate in invited talks regarding their work to discover and develop
medicines that target the underlying cause of CF. The Full Research Report on
Vertex Pharmaceuticals Incorporated - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX]

--

Celgene Corporation Research Report

On September 6, 2013, Celgene Corp. (Celgene) announced that the Company has
received an approval from the U.S. Food and Drug Administration (FDA) for its
supplemental New Drug Application (sNDA) of ABRAXANE, as first-line treatment
for patients with metastatic adenocarcinoma of the pancreas, in combination
with gemcitabine. Jean-Pierre Bizzari, M.D., Executive Vice President of
Hematology and Oncology for Celgene Corporation commented, "The addition of
ABRAXANE to gemcitabine demonstrated meaningful improvements across key
efficacy outcomes, including overall survival, with a well-characterized
safety profile." The Full Research Report on Celgene Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7f47_CELG]

--

NPS Pharmaceuticals, Inc. Research Report

On September 10, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals)
announced the appointment of President and CEO Francois Nader, M.D. to the
Biotechnology Industry Organization's (BIO's) Board of Directors as a member
of the Health Section Governing Board. The Company said that BIO is the
world's largest biotechnology trade association and represents more than 1,100
biotechnology companies, academic institutions, state biotechnology centers
and related organizations across the United States and in more than 30 other
nations. "It's a pleasure to serve on the BIO board alongside many of the
biotechnology industry's leading executives," said Dr. Nader. "I share BIO's
commitment to promoting biomedical innovation and finding ways to reduce
hurdles to life-saving therapies." The Full Research Report on NPS
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/441a_NPSP]

--

Cyclacel Pharmaceuticals, Inc. Research Report

On September 19, 2013, Cyclacel Pharmaceuticals, Inc. (Cyclacel) provided
updated data showing that Sapacitabine, an orally-available nucleoside
analogue, has activity against a majority of ovarian cancer samples taken from
patients, including resistant tumors. "We are encouraged by the activity
signal of sapacitabine in ovarian cancer samples," said Judy Chiao, M.D., Vice
President, Clinical Development and Regulatory Affairs of Cyclacel. "This
observation may be directly related to the drug's mechanism which is enhanced
in cancer cells with reduced capacity for DNA repair through the homologous
recombination repair or HR pathway." According to Cyclacel, the reported data
further support the potential for sapacitabine to be used as a treatment for
HR defective cancers, such as ATM- or BRCA-defective tumors. The Company also
informed that clinical trials examining the activity of sapacitabine in
ATM-defective CLL, and of sapacitabine in combination with Cyclacel's
seliciclib in cancer patients with BRCA1 or BRCA2 mutations, are currently in
progress. The Full Research Report on Cyclacel Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/fa88_CYCC]

--

BioCryst Pharmaceuticals, Inc. Research Report

On September 17, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced
that it has been awarded a contract by the National Institute of Allergy and
Infectious Diseases (NIAID) to develop BCX4430 as a treatment for Marburg
virus disease. NIAID, which is a part of the National Institutes of Health has
made an initial award of $5.0 million to BioCryst. According to BioCryst, the
contract aims to file investigational new drug (IND) applications for
intravenous (i.v.) and intramuscular (i.m.) BCX4430 for the treatment of
Marburg virus disease, and to conduct an initial Phase 1 human clinical trial.
Also, as per the Company, the contract supports the appropriate IND-enabling
program and the initial clinical trial. The Full Research Report on BioCryst
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.